LXRX - Lexicon Pharmaceuticals Inc
IEX Last Trade
1.73
-0.070 -4.046%
Share volume: 3,307,233
Last Updated: Fri 30 Aug 2024 09:59:51 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.80
-0.07
-3.89%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-09 | 2023-03-03 | 2023-05-04 | 2023-08-04 | 2023-11-08 | 2024-03-25 | 2024-05-02 | 2024-08-02 | |
| Assets | |||||||||
| Total Assets | 191.685 M | 194.299 M | 162.716 M | 316.724 M | 276.479 M | 229.429 M | 417.219 M | 373.356 M | |
| Current Assets | 139.063 M | 140.866 M | 109.546 M | 263.720 M | 223.372 M | 176.547 M | 364.647 M | 320.844 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 172.000 K | 336.000 K | 381.000 K | 514.000 K | 585.000 K | |
| Other Current Assets | 2.821 M | 2.481 M | 3.348 M | 6.124 M | 4.291 M | 5.130 M | 7.009 M | 7.675 M | |
| Short Term Investments | 2.821 M | 2.481 M | 3.348 M | 6.124 M | 4.291 M | 5.130 M | 7.009 M | 7.675 M | |
| Total Receivables | 39.000 K | 28.000 K | 261.000 K | 685.000 K | 318.000 K | 1.010 M | 1.526 M | 2.620 M | |
| Current Cash | 136.203 M | 138.357 M | 105.937 M | 256.739 M | 218.427 M | 170.026 M | 355.598 M | 309.964 M | |
| Total Non-current Assets | 52.622 M | 53.433 M | 53.170 M | 53.004 M | 53.107 M | 52.882 M | 52.572 M | 52.512 M | |
| Property Plant Equipment | 932.000 K | 2.071 M | 2.207 M | 2.202 M | 2.134 M | 1.987 M | 1.843 M | 1.954 M | |
| Other Assets | 7.147 M | 0.000 | 0.000 | 0.000 | 0.000 | 828.000 K | 828.000 K | 828.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 44.543 M | 44.543 M | 44.543 M | 44.543 M | 44.543 M | 44.543 M | 44.543 M | 44.543 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 191.685 M | 194.299 M | 162.716 M | 316.724 M | 276.479 M | 229.429 M | 417.219 M | 373.356 M | |
| Total liabilities | 47.667 M | 77.175 M | 74.670 M | 130.363 M | 136.969 M | 136.319 M | 128.352 M | 133.376 M | |
| Total current liabilities | 18.445 M | 23.172 M | 20.371 M | 26.109 M | 32.261 M | 31.546 M | 23.399 M | 27.876 M | |
| Accounts Payable | 9.427 M | 10.395 M | 10.311 M | 10.501 M | 12.036 M | 14.389 M | 8.067 M | 12.220 M | |
| Other liabilities | 5.438 M | 5.424 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 6.001 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 23.784 M | 48.579 M | 48.845 M | 98.772 M | 99.265 M | 99.508 M | 99.874 M | 99.499 M | |
| Other liabilities | 5.438 M | 5.424 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 6.001 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 144.018 M | 117.124 M | 88.046 M | 186.361 M | 139.510 M | 93.110 M | 288.867 M | 239.980 M | |
| Common stock | 174.904 M | 189.262 M | 189.014 M | 204.783 M | 244.925 M | 245.798 M | 245.390 M | 310.836 M | |
| Retained earnings | -1.559 B | -1.590 B | -1.622 B | -1.667 B | -1.717 B | -1.767 B | -1.815 B | -1.869 B |